Empagliflozin in Patients with Chronic Kidney Disease

William G. Herrington , Natalie Staplin , Christoph Wanner , William G. Herrington , Natalie Staplin , Christoph Wanner , Jennifer B. Green , Sibylle J. Hauske , Jonathan Emberson , David Preiss , Parminder K. Judge , Kaitlin J. Mayne , Sarah Y A Ng , Emily Sammons , Doreen Zhu , Michael Hill , Will Stevens , Karl Wallendszus , Susanne Brenner , Alfred K. Cheung , Zhihong Liu , Jing Li , Lai Seong Hooi , Wen Liu , Takashi Kadowaki , Masaomi Nangaku , Adeera Levin , David Z.I. Cherney , Aldo P. Maggioni , Roberto Pontremoli , Rajat Deo , Shinya Goto , Xavier Rosselló , Katherine R. Tuttle , Dominik Steubl , Michaela Petrini , Dan Massey , Jens Eilbracht , Martina Brueckmann , Martin Landray , Colin Baigent , Richard Haynes
2022 New England Journal of Medicine 1,959 citations

Abstract

Among a wide range of patients with chronic kidney disease who were at risk for disease progression, empagliflozin therapy led to a lower risk of progression of kidney disease or death from cardiovascular causes than placebo. (Funded by Boehringer Ingelheim and others; EMPA-KIDNEY ClinicalTrials.gov number, NCT03594110; EudraCT number, 2017-002971-24.).

Keywords

EmpagliflozinMedicineKidney diseaseDiseaseEMPAInternal medicineIntensive care medicineDiabetes mellitusEndocrinologyType 2 diabetes

Affiliated Institutions

Related Publications

Publication Info

Year
2022
Type
article
Volume
388
Issue
2
Pages
117-127
Citations
1959
Access
Closed

External Links

View on DOI.org

Social Impact

Altmetric
PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1959
OpenAlex

Cite This

William G. Herrington, Natalie Staplin, Christoph Wanner et al. (2022). Empagliflozin in Patients with Chronic Kidney Disease. New England Journal of Medicine , 388 (2) , 117-127. https://doi.org/10.1056/nejmoa2204233

Identifiers

DOI
10.1056/nejmoa2204233